Redhill Biopharma (RDHL) Competitors

$0.98 0.00 (0.00%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$0.97 -0.01 (-1.01%)

As of 05/22/2026 06:36 PM Eastern

RDHL vs. KTTA, ANEB, LPCN, TRAW, and ZIVO

Should you buy Redhill Biopharma stock or one of its competitors? MarketBeat compares Redhill Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Redhill Biopharma include Pasithea Therapeutics (KTTA), Anebulo Pharmaceuticals (ANEB), Lipocine (LPCN), Traws Pharma (TRAW), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does Redhill Biopharma compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Pasithea Therapeutics had 7 more articles in the media than Redhill Biopharma. MarketBeat recorded 7 mentions for Pasithea Therapeutics and 0 mentions for Redhill Biopharma. Pasithea Therapeutics' average media sentiment score of 0.75 beat Redhill Biopharma's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Positive
Redhill Biopharma	Neutral

Pasithea Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its share price is 405% more volatile than the broader market.

Pasithea Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 328.69%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Redhill Biopharma	N/A	N/A	N/A

Redhill Biopharma has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Redhill Biopharma	$290K	17.54	-$430K	$1.05 thousand	0.00

Summary

Redhill Biopharma beats Pasithea Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Anebulo Pharmaceuticals?

Redhill Biopharma (NASDAQ:RDHL) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Redhill Biopharma's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Redhill Biopharma has a beta of 5.05, suggesting that its share price is 405% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the broader market.

In the previous week, Anebulo Pharmaceuticals had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 1 mentions for Anebulo Pharmaceuticals and 0 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Anebulo Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Redhill Biopharma has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	17.54	-$430K	$1.05 thousand	0.00
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

Redhill Biopharma beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Lipocine?

Redhill Biopharma (NASDAQ:RDHL) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Redhill Biopharma has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	17.54	-$430K	$1.05 thousand	0.00
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A

In the previous week, Lipocine had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Lipocine	Neutral

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Redhill Biopharma has a beta of 5.05, indicating that its share price is 405% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Redhill Biopharma has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Redhill Biopharma's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Lipocine	-571.18%	-66.70%	-59.39%

Summary

Redhill Biopharma beats Lipocine on 9 of the 15 factors compared between the two stocks.

How does Redhill Biopharma compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Redhill Biopharma's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Redhill Biopharma	N/A	N/A	N/A

Traws Pharma presently has a consensus target price of $8.00, suggesting a potential upside of 436.91%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Traws Pharma has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its stock price is 405% more volatile than the broader market.

Traws Pharma has higher revenue and earnings than Redhill Biopharma. Traws Pharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	5.43	$9.17M	-$1.69	N/A
Redhill Biopharma	$290K	17.54	-$430K	$1.05 thousand	0.00

In the previous week, Traws Pharma had 11 more articles in the media than Redhill Biopharma. MarketBeat recorded 11 mentions for Traws Pharma and 0 mentions for Redhill Biopharma. Traws Pharma's average media sentiment score of 0.56 beat Redhill Biopharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Positive
Redhill Biopharma	Neutral

Summary

Traws Pharma beats Redhill Biopharma on 10 of the 16 factors compared between the two stocks.

How does Redhill Biopharma compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

ZIVO Bioscience has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 5.05, meaning that its share price is 405% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,075.20	-$7.78M	-$1.71	N/A
Redhill Biopharma	$290K	17.54	-$430K	$1.05 thousand	0.00

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Redhill Biopharma	N/A	N/A	N/A

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Redhill Biopharma	Neutral

Summary

Redhill Biopharma beats ZIVO Bioscience on 7 of the 10 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.09M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	0.00	17.79	21.00	25.66
Price / Sales	17.54	336.21	558.19	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	1.18	5.86	10.40	7.14
Net Income	-$430K	$74.99M	$3.57B	$335.98M
7 Day Performance	5.58%	3.11%	6.40%	4.11%
1 Month Performance	-4.40%	-3.05%	3.55%	2.52%
1 Year Performance	-46.74%	34.38%	34.13%	35.04%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	0.629 of 5 stars	$0.98 flat	N/A	-46.7%	$5.09M	$290K	0.00	210	Gap Down
KTTA Pasithea Therapeutics	2.798 of 5 stars	$0.70 -8.8%	$3.00 +327.0%	-23.5%	$19.20M	N/A	N/A	3	News Coverage Analyst Revision Gap Up
ANEB Anebulo Pharmaceuticals	0.0325 of 5 stars	$0.46 -9.7%	N/A	-58.9%	$18.76M	N/A	N/A	4	Gap Up
LPCN Lipocine	2.9104 of 5 stars	$2.20 -0.5%	$15.00 +581.8%	-36.9%	$18.22M	$1.98M	N/A	10
TRAW Traws Pharma	3.2137 of 5 stars	$1.59 -9.7%	$8.00 +403.1%	+13.7%	$17.88M	$2.79M	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. KTTA, ANEB, LPCN, TRAW, and ZIVO

How does Redhill Biopharma compare to Pasithea Therapeutics?

Summary

How does Redhill Biopharma compare to Anebulo Pharmaceuticals?

Summary

How does Redhill Biopharma compare to Lipocine?

Summary

How does Redhill Biopharma compare to Traws Pharma?

Summary

How does Redhill Biopharma compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. KTTA, ANEB, LPCN, TRAW, and ZIVO

How does Redhill Biopharma compare to Pasithea Therapeutics?

Do insiders & institutionals have more ownership in KTTA or RDHL?

Does the media refer more to KTTA or RDHL?

Which has more volatility and risk, KTTA or RDHL?

Do analysts rate KTTA or RDHL?

Is KTTA or RDHL more profitable?

Which has preferable earnings & valuation, KTTA or RDHL?

Summary

How does Redhill Biopharma compare to Anebulo Pharmaceuticals?

Is RDHL or ANEB more profitable?

Do insiders and institutionals hold more shares of RDHL or ANEB?

Which has more risk and volatility, RDHL or ANEB?

Does the media prefer RDHL or ANEB?

Do analysts prefer RDHL or ANEB?

Which has better earnings and valuation, RDHL or ANEB?

Summary

How does Redhill Biopharma compare to Lipocine?

Which has better valuation & earnings, RDHL or LPCN?

Does the media refer more to RDHL or LPCN?

Do analysts prefer RDHL or LPCN?

Which has more risk & volatility, RDHL or LPCN?

Do insiders & institutionals hold more shares of RDHL or LPCN?

Is RDHL or LPCN more profitable?

Summary

How does Redhill Biopharma compare to Traws Pharma?

Do insiders and institutionals hold more shares of TRAW or RDHL?

Is TRAW or RDHL more profitable?

Do analysts recommend TRAW or RDHL?

Which has more risk & volatility, TRAW or RDHL?

Which has better earnings & valuation, TRAW or RDHL?

Does the media refer more to TRAW or RDHL?

Summary

How does Redhill Biopharma compare to ZIVO Bioscience?

Which has more volatility and risk, ZIVO or RDHL?

Do analysts rate ZIVO or RDHL?

Which has better valuation and earnings, ZIVO or RDHL?

Is ZIVO or RDHL more profitable?

Do insiders & institutionals hold more shares of ZIVO or RDHL?

Does the media favor ZIVO or RDHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools